Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 5/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663210 | 0.92 | HINT1 (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL1611244 | 0.91 | HINT1 (0.77) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL4371108 | 0.89 | HINT1 (0.63) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL2337631 | 0.88 | HINT1 (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL6397385 | 0.88 | HINT1 (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL7151774 | 0.86 | HINT1 (0.63) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL16360143 | 0.86 | HPGD (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL222316 | 0.86 | HPGD (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL12150640 | 0.86 | HPGD (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 | |
| SCHEMBL16198946 | 0.86 | HPGD (0.61) | HINT1GSK3ARPS6KA3MAPK14TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RIBOZYME PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6586238-B1 | Modified ribozymes; useful for cleavage of RNA or single-stranded DNA; Resistance to exonuclease degradation | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RNGTT, MTAP, RNASEL | HINT1 101/4885GSK3A 4229/4885RPS6KA3 1861/4885 |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | HINT1 184/4885GSK3A 1134/4885RPS6KA3 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.